GAP Coinvestments CDA, L.P.'s Form 4 filing
CinCor Pharma, Inc. (CINC) · filed Jan 13, 2022
- Accession no.
- 0000950142-22-000344
- Filed
- Jan 13, 2022, 9:32 PM ET
- Trade date
- Jan 11, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market purchases total $27.2M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| GAP Coinvestments CDA, L.P.CIK 0001356474 | 10% Owner |
| GAP (Bermuda) L.P.CIK 0001406817 | 10% Owner |
| General Atlantic Genpar (Bermuda), L.P.CIK 0001467927 | 10% Owner |
| General Atlantic (SPV) GP, LLCCIK 0001793940 | 10% Owner |
| General Atlantic (CIN), L.P.CIK 0001891495 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 11, 2022 | Common Stock, par value $0.00001 per share ("Common Stock") | CConversionAcquired | +2,426,470 | –F1 | – | 2,426,470 | Indirect | Duplicate filing |
| Jan 11, 2022 | Common Stock | PPurchaseAcquired | +1,700,000 | $16.00 | +$27,200,000 | 4,126,470 | Indirect | Duplicate filing |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 11, 2022 | Common stock | CConversionDisposed | −2,426,470 | –F1 | – | 0 | Indirect | Duplicate filing |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Represents the automatic conversion of Series B Preferred Stock into shares of Common Stock of CinCor Pharma, Inc. (" the Issuer"), on a 3.4:1 basis immediately prior to the closing of the Issuer's initial public offering (the "IPO") which closed on January 11, 2022.
Referenced by the price of 1 transaction in Table I and 1 transaction in Table II.
Remarks
GA CIN, the GA Funds, GA SPV, GA GenPar Lux, GA Lux, GenPar Bermuda, GAP (Bermuda) LP, GA GenPar, and GA LP may be deemed to be members of a "group" for the purposes of the Securities Exchange Act of 1934. Each reporting person disclaims beneficial ownership of any securities deemed to be owned by the group that are not directly owned by the reporting person. This report shall not be deemed an admission that the reporting persons are a member of a group or the beneficial owner of any securities not directly owned by the reporting person. // Form 2 of 2.